113 related articles for article (PubMed ID: 22281290)
1. Pro-apoptotic effects of Amblyomin-X in murine renal cell carcinoma "in vitro".
Akagi EM; Júnior PL; Simons SM; Bellini MH; Barreto SA; Chudzinski-Tavassi AM
Biomed Pharmacother; 2012 Feb; 66(1):64-9. PubMed ID: 22281290
[TBL] [Abstract][Full Text] [Related]
2. Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model.
de Souza JG; Morais KL; Anglés-Cano E; Boufleur P; de Mello ES; Maria DA; Origassa CS; de Campos Zampolli H; Câmara NO; Berra CM; Bosch RV; Chudzinski-Tavassi AM
Oncotarget; 2016 Sep; 7(38):62255-62266. PubMed ID: 27566592
[TBL] [Abstract][Full Text] [Related]
3. Specific role of cytoplasmic dynein in the mechanism of action of an antitumor molecule, Amblyomin-X.
Pacheco MT; Morais KL; Berra CM; Demasi M; Sciani JM; Branco VG; Bosch RV; Iqbal A; Chudzinski-Tavassi AM
Exp Cell Res; 2016 Jan; 340(2):248-58. PubMed ID: 26748183
[TBL] [Abstract][Full Text] [Related]
4. Dynein function and protein clearance changes in tumor cells induced by a Kunitz-type molecule, Amblyomin-X.
Pacheco MT; Berra CM; Morais KL; Sciani JM; Branco VG; Bosch RV; Chudzinski-Tavassi AM
PLoS One; 2014; 9(12):e111907. PubMed ID: 25479096
[TBL] [Abstract][Full Text] [Related]
5. A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production.
Maria DA; de Souza JG; Morais KL; Berra CM; Zampolli Hde C; Demasi M; Simons SM; de Freitas Saito R; Chammas R; Chudzinski-Tavassi AM
Invest New Drugs; 2013 Jun; 31(3):493-505. PubMed ID: 22975862
[TBL] [Abstract][Full Text] [Related]
6. Amblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXa and induces anticoagulation in vitro and in vivo.
Branco VG; Iqbal A; Alvarez-Flores MP; Sciani JM; de Andrade SA; Iwai LK; Serrano SM; Chudzinski-Tavassi AM
Biochim Biophys Acta; 2016 Oct; 1864(10):1428-35. PubMed ID: 27479486
[TBL] [Abstract][Full Text] [Related]
7. Post-transcriptional control of Amblyomin-X on secretion of vascular endothelial growth factor and expression of adhesion molecules in endothelial cells.
Drewes CC; Dias RY; Branco VG; Cavalcante MF; Souza JG; Abdalla DS; Chudzinski-Tavassi AM; Farsky SH
Toxicon; 2015 Jul; 101():1-10. PubMed ID: 25912945
[TBL] [Abstract][Full Text] [Related]
8. Actions of the Kunitz-type serine protease inhibitor Amblyomin-X on VEGF-A-induced angiogenesis.
Drewes CC; Dias RY; Hebeda CB; Simons SM; Barreto SA; Ferreira JM; Chudzinski-Tavassi AM; Farsky SH
Toxicon; 2012 Sep; 60(3):333-40. PubMed ID: 22575283
[TBL] [Abstract][Full Text] [Related]
9. Tick salivary gland as potential natural source for the discovery of promising antitumor drug candidates.
Chudzinski-Tavassi AM; Morais KL; Pacheco MT; Pasqualoto KF; de Souza JG
Biomed Pharmacother; 2016 Feb; 77():14-9. PubMed ID: 26796259
[TBL] [Abstract][Full Text] [Related]
10. A new tick Kunitz type inhibitor, Amblyomin-X, induces tumor cell death by modulating genes related to the cell cycle and targeting the ubiquitin-proteasome system.
Chudzinski-Tavassi AM; De-Sá-Júnior PL; Simons SM; Maria DA; de Souza Ventura J; Batista IF; Faria F; Durães E; Reis EM; Demasi M
Toxicon; 2010 Dec; 56(7):1145-54. PubMed ID: 20570593
[TBL] [Abstract][Full Text] [Related]
11. New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X.
Pavon LF; Capper D; Sibov TT; de Toledo SRC; Thomale UW; de Souza JG; Cabral FR; Berra CM; Silva da Costa MD; Mendonça Niçacio J; Dastoli PA; de Oliveira DM; Malheiros SMF; da Cruz EF; Malheiros JM; de Oliveira SM; Silva NS; Petrilli AS; Cappellano AM; Brunialti MC; Salomão R; de Paiva Neto MA; Chudzinski-Tavassi AM; Cavalheiro S
Sci Rep; 2019 Jul; 9(1):9973. PubMed ID: 31292491
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of an imidazoquinoline in renal cell carcinoma.
Schwartz MJ; Liu H; Hwang DH; Kawamoto H; Scherr DS
Urology; 2009 May; 73(5):1156-62. PubMed ID: 19118885
[TBL] [Abstract][Full Text] [Related]
13. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
[TBL] [Abstract][Full Text] [Related]
14. Amblyomin-X induces ER stress, mitochondrial dysfunction, and caspase activation in human melanoma and pancreatic tumor cell.
Morais KL; Pacheco MT; Berra CM; Bosch RV; Sciani JM; Chammas R; de Freitas Saito R; Iqbal A; Chudzinski-Tavassi AM
Mol Cell Biochem; 2016 Apr; 415(1-2):119-31. PubMed ID: 27015684
[TBL] [Abstract][Full Text] [Related]
15. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.
Wang Z; Liu S; Ding K; Ding S; Li C; Lu J; Gao D; Zhang T; Bi D
Tumour Biol; 2016 Nov; 37(11):15133-15143. PubMed ID: 27677286
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs.
Kim EA; Kim SW; Nam J; Sung EG; Song IH; Kim JY; Kwon TK; Lee TJ
Oncotarget; 2016 May; 7(22):31832-46. PubMed ID: 27092874
[TBL] [Abstract][Full Text] [Related]
17. Amblyomin-X, a recombinant Kunitz-type inhibitor, regulates cell adhesion and migration of human tumor cells.
Schmidt MCB; Morais KLP; Almeida MES; Iqbal A; Goldfeder MB; Chudzinski-Tavassi AM
Cell Adh Migr; 2020 Dec; 14(1):129-138. PubMed ID: 30238848
[TBL] [Abstract][Full Text] [Related]
18. Targeting neddylation pathway with MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis in renal cell carcinoma.
Wang J; Wang S; Zhang W; Wang X; Liu X; Liu L; Li L; Liang Y; Yu J; Jeong LS; Jia L; Zhao H; Zhang Y
Biochem Biophys Res Commun; 2017 Sep; 490(4):1183-1188. PubMed ID: 28669728
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution and Pharmacokinetics of Amblyomin-X, a Novel Antitumour Protein Drug in Healthy Mice.
Boufleur P; Sciani JM; Goldfeder M; Faria F; Branco V; Chudzinski-Tavassi AM
Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):111-120. PubMed ID: 30132264
[TBL] [Abstract][Full Text] [Related]
20. Anticancer activity of Schiff base-Poloxamer P85 combination against kidney cancer.
Doğan A; Demirci S; Telci D; Canikyan S; Kongur M; Dede B; Şahin F
Int Urol Nephrol; 2018 Feb; 50(2):247-255. PubMed ID: 29288416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
